HSV innovation - mRNA-1608

Moderna's mRNA-1608 is an innovative vaccine candidate under development targeting herpes simplex virus (HSV), a latent virus capable of causing recurring infections. HSV exists in two main types: HSV-1, which often causes oral and genital sores, and HSV-2, primarily associated with genital infections. Both types establish latency in the body, meaning they remain dormant in nerve cells and can reactivate under certain conditions.

Currently, mRNA-1608 is in Phase 2 clinical trials, focusing on assessing its safety, immunogenicity (the ability to provoke an immune response), and efficacy. This vaccine uses Moderna's mRNA technology, which has been pivotal in other vaccines, to train the immune system to recognize and combat HSV. The goal is to reduce the frequency and severity of outbreaks and potentially limit the virus's ability to reactivate, improving the quality of life for those affected